Summit Therapeutics (SMMT, Financial) received a reiterated rating from JMP Securities, with analyst Reni Benjamin maintaining a "Market Outperform" rating. The announcement was made on June 2, 2025.
Reni Benjamin reaffirmed the price target for Summit Therapeutics (SMMT, Financial) at $40.00 USD, which remains unchanged from the prior assessment. This suggests confidence in the company's current market position and potential growth prospects.
The analyst's consistent market outperform rating indicates a positive outlook for Summit Therapeutics (SMMT, Financial), suggesting that the stock is expected to perform better than the average market return.
Investors will be closely monitoring how Summit Therapeutics (SMMT, Financial) continues to develop and respond to market conditions, following JMP Securities' reiterated outlook.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Summit Therapeutics Inc (SMMT, Financial) is $33.78 with a high estimate of $44.00 and a low estimate of $5.00. The average target implies an upside of 94.68% from the current price of $17.35. More detailed estimate data can be found on the Summit Therapeutics Inc (SMMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Summit Therapeutics Inc's (SMMT, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
